Cardiomyopathy

Cardiovascular
1
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
2 programs
1
RanexaPhase 41 trial
RanolazineN/A1 trial
Active Trials
NCT01705509Terminated14Est. Mar 2017
NCT01345188Completed28Est. Apr 2014
Abbott
AbbottABBOTT PARK, IL
1 program
"Sequential Arm"N/A1 trial
Active Trials
NCT00737490Completed40Est. Jul 2011
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Darbepoetin alfaN/A1 trial
Active Trials
NCT00883415Completed20Est. Nov 2012
Tenaya Therapeutics
Tenaya TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated CardiomyopathyN/A1 trial
Active Trials
NCT05112237RecruitingEst. Jun 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Gilead SciencesRanexa
Tenaya TherapeuticsNatural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
Gilead SciencesRanolazine
AmgenDarbepoetin alfa
Abbott"Sequential Arm"

Clinical Trials (5)

Total enrollment: 102 patients across 5 trials

NCT01345188Gilead SciencesRanexa

Ranolazine in Ischemic Cardiomyopathy

Start: Apr 2011Est. completion: Apr 201428 patients
Phase 4Completed
NCT05112237Tenaya TherapeuticsNatural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

Start: Nov 2021Est. completion: Jun 2028
N/ARecruiting
NCT01705509Gilead SciencesRanolazine

The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

Start: Sep 2012Est. completion: Mar 201714 patients
N/ATerminated
NCT00883415AmgenDarbepoetin alfa

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

Start: May 2008Est. completion: Nov 201220 patients
N/ACompleted
NCT00737490Abbott"Sequential Arm"

Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)

Start: Jun 2005Est. completion: Jul 201140 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
21h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
22h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
22h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
22h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
22h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 102 patients
4 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)